Abstract:Background While the past decades have seen an explosion of innovation in immunotherapies, most have failed in their clinical studies. One of the barriers encountered across these trials is that despite demonstrated cytoxicity, tumor immune evasion renders these treatments ineffective. Glioblastoma (GBM) is one of these tumors where experimental immunotherapeutics have continued to fail. The median survival of GBM remains at 15 months with the primary treatment being surgical resection, radiation, and chemotherapeutic over the past decade. To breach this stalemate, we require new therapeutics that both can target tumor immune evasion and can balance efficacy with toxicity. Our lab previously developed a subcutaneous autologous tumor vaccine utilizing a phagocytosis-stimulating ligand mannan anchored to irradiated (IR) tumor cells with the adjuvants toll-like receptor (TLR) agonists and immunostimulant anti-CD40 antibody (collectively abbreviated as MBTA). This regime allowed recognition of tumors resulting in a coordinated innate and adaptive immune response in both prophylactic and therapeutic studies with colon carcinoma, breast tumor, and GBM mouse models. The aim of our study was to generate a dendritic cell (DC) vaccine utilizing this strategy. Methods To assess if MBTA anchored GBM cells could mature DCs in-vitro, we harvested bone-marrow DCs (BMDCs) from mice and co-cultured them with MBTA GBM cells for 24 hours. Analysis was performed by flow cytometry and ELISA to confirm maturation markers and DC phenotype. To assess if MBTA DCs could protect against tumor metastasis, we utilized a melanoma (B16) prophylactic model by vaccinating mice 1 week before tail vein melanoma challenge. Results We found robust up-regulation of co-stimulatory molecules CD40, CD80 and CD86 and preferential upregulation of MHCI in the MBTA group with ELISA analysis demonstrating MBTA DCs significantly upregulated Type 1 cytokines (TNFa and IL-6) and limited regulatory cytokine (IL-10) secretion across GBM cell lines. Mice vaccinated with MBTA DCs had a significant decrease in lung metastasis compared to controls with lung immunohistochemistry demonstrating robust perivascular lymphocytic infiltration. Currently, we are working on demonstrating this efficacy in a glioblastoma model. Conclusions Collectively our results demonstrate that MBTA is an effective strategy to mature and load tumor antigens onto DCs ex-vivo. It has efficacy as a DC vaccine to prevent melanoma metastasis and potential as a glioblastoma DC vaccine. Acknowledgements The authors acknowledge the NCI-CCR affiliated staff for their assistance with animal housing and the NCI CCR Flow Cytometry Core Members for their expertise in flow cytometry Ethics Approval The National Cancer Institute (NCI) Animal Use and Care Committees approved the present study under NOB-010 and NOB-016.

Construction of recombinant adenovirus Ad5/F35-MAGE-A3 and its effect on maturation and apoptosis of dendritic cells in patients with melanoma

Proliferative effect of MAGE-A9 deletion mutant on human breast cancer MCF-7 cells

[Immune Response of Melanoma Antigen Gene-3 Modified Dendritic Cell Vaccines in Gastric Carcinoma].

The effect of MAGE-A1 gene on NIH3T3 cells

Anti-gastric carcinoma efficacy of gene modified dendritic cell vaccine recruited by macrophage inflammation protein-1

CCL3 and CCL20-recruited Dendritic Cells Modified by Melanoma Antigen Gene-1 Induce Anti-Tumor Immunity Against Gastric Cancer Ex Vivo and in Vivo

[Study of the Cytotoxity Against Human Hepatocellular Carcinoma Cells Induced by the MAGE-1 Gene Modified Dendritic Cells].

Preliminary study on antitumor effect of C215gene transfected tumor vaccine and monoclonal antibody-superantigen fusion protein C 215Fab-SEA

[Inhibitory Effect of Dendritic Cells Pulsed with MAGE-3 Peptide on Transplanted Murine Gastric Cancer in Mice].

425 A Novel Dendritic Cell Vaccine Utilizing Mannan Anchored to Irradiated Tumor Cells in the Presence of Immune Adjuvants

Anti-gastric cancer immunity of MAGE-3 retrogen-transfected dendritic cells

The Cell-mediated Immunoenhancement of Different Adjuvants on the Murine Melanoma Vaccine

Construction and Identification of Recombinant Lentiviral Vector Containing Human MAGE-A3 Gene and Its Expression in Lung Cancer Cells

Intratumoral Administration of Immature Dendritic Cells Following the Adenovirus Vector Encoding CD40 Ligand Elicits Significant Regression of Established Myeloma

Construction of Recombinant Adenovirus Harboring Fusion Gene NT4p53(C22)Ant and Its Killing Effect on HepG2 Tumor Cells

Therapeutic Effect of Combined Treatment with CD Suicide Gene and GM-CSF Gene on Murine Melanoma and Its Immunological Mechanism

[The Influence of Ad-AVEGF165 on Human Malignant Melanoma Growth in Nude Mice].

[Enhanced Transduction Efficiency of Adeno-Associated Virus on Cancer Cells with the Help of Low Dose Adenovirus].

Adenovirus-mediated XAF1 Gene Expression Induces Apoptosis in Human Hepatocellular Carcinoma Cell Line SMMC7721

Construction and Identification of Recombinant Adeno-Associated Virus Vector Harboring Fusion Gene NT4-Apoptin-HA2-TAT

L-Rhamnose Enhances the Immunogenicity of Melanoma-Associated Antigen A3 for Stimulating Antitumor Immune Responses.